Thiopurine treatment in patients with Crohn's disease leads to a selective reduction of an effector cytotoxic gene expression signature revealed by whole-genome expression profiling

Molecular Immunology

Volumn 54, Issue 3-4, 2013, Pages 472-481

  Bouma, G ^a   Baggen, J M ^a   van Bodegraven, A A ^a   Mulder, C J J ^a   Kraal, G ^a   Zwiers, A ^a   Horrevoets, A J ^a   van der Pouw Kraan, C T M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD160; Microarrays; NK cells; Thiopurines (derivatives); TLR4

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CD94 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CXCL2 CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE II; INTERLEUKIN 10 RECEPTOR BETA; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 23P19; INTERLEUKIN 3; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5; INTERLEUKIN 6 RECEPTOR ALPHA; INTERLEUKIN 8; LYMPHOTOXIN BETA RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MERCAPTOPURINE; SOMATOMEDIN B RECEPTOR; STAT5A PROTEIN; STAT5B PROTEIN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR III; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SP3; UNINDEXED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOTOXICITY; DRUG EFFECT; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENOTYPE; HUMAN; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; UPREGULATION;

6-MERCAPTOPURINE; ADULT; ANTIGENS, CD; AZATHIOPRINE; CELLS, CULTURED; CHEMOKINES; CROHN DISEASE; FEMALE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTERFERONS; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; MALE; RIBOSOMES; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTORS; TRANSCRIPTOME; UP-REGULATION;

EID: 84874364813     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.01.015     Document Type: Article

References (54)

1. Aloi M., Tromba L., Di N.G., Dilillo A., Del G.E., Marocchi E., Viola F., Civitelli F., Berni A., Cucchiara S. Premature subclinical atherosclerosis in pediatric inflammatory bowel disease. The Journal of Pediatrics 2012, 161:589-594.
2. Anumanthan A., Bensussan A., Boumsell L., Christ A.D., Blumberg R.S., Voss S.D., Patel A.T., Robertson M.J., Nadler L.M., Freeman G.J. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. Journal of Immunology 1998, 161:2780-2790.
3. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., Frees K., Watt J.L., Schwartz D.A. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genetics 2000, 25:187-191.
4. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., Shark K.B., Grande W.J., Hughes K.M., Kapur V., Gregersen P.K., Behrens T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:2610-2615.
5. Barakonyi A., Rabot M., Marie-Cardine A., Guerre-Girr M., Polgar B., Schiavon V., Bensussan A., Le B.P. Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset. Journal of Immunology 2004, 173:5349-5354.
6. Barrett J.C., Hansoul S., Nicolae D.L., Cho J.H., Duerr R.H., Rioux J.D., Brant S.R., Silverberg M.S., Taylor K.D., Barmada M.M., Bitton A., Dassopoulos T., Datta L.W., Green T., Griffiths A.M., Kistner E.O., Murtha M.T., Regueiro M.D., Rotter J.I., Schumm L.P., Steinhart A.H., Targan S.R., Xavier R.J., Libioulle C., Sandor C., Lathrop M., Belaiche J., Dewit O., Gut I., Heath S., Laukens D., Mni M., Rutgeerts P., Van G.A., Zelenika D., Franchimont D., Hugot J.P., de V.M., Vermeire S., Louis E., Cardon L.R., Anderson C.A., Drummond H., Nimmo E., Ahmad T., Prescott N.J., Onnie C.M., Fisher S.A., Marchini J., Ghori J., Bumpstead S., Gwilliam R., Tremelling M., Deloukas P., Mansfield J., Jewell D., Satsangi J., Mathew C.G., Parkes M., Georges M., Daly M.J. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nature Genetics 2008, 40:955-962.
7. Bos C.L., van Baarsen L.G., Timmer T.C., Overbeek M.J., Basoski N.M., Rustenburg F., Baggen J.M., Thiesen H.J., Dijkmans B.A., van der Pouw Kraan T.C., Voskuyl A.E., Verweij C.L. Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers. Genes and Immunity 2009, 10:210-218.
8. Brenner O., Levanon D., Negreanu V., Golubkov O., Fainaru O., Woolf E., Groner Y. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:16016-16021.
9. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends in Immunology 2001, 22:633-640.
10. Cruz-Guilloty F., Pipkin M.E., Djuretic I.M., Levanon D., Lotem J., Lichtenheld M.G., Groner Y., Rao A. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. Journal of Experimental Medicine 2009, 206:51-59.
11. + T cells. Immunity 2009, 31:823-833.
12. Eisen M.B., Spellman P.T., Brown P.O., Botstein D. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:14863-14868.
13. Elion G.B. The George Hitchings and Gertrude Elion lecture. The pharmacology of azathioprine. Annals of the New York Academy of Sciences 1993, 685:400-407.
14. Erridge C., Stewart J., Poxton I.R. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. Journal of Experimental Medicine 2003, 197:1787-1791.
15. Franchimont D., Vermeire S., El H.H., Pierik M., Van S.K., Gustot T., Quertinmont E., Abramowicz M., Van G.A., Deviere J., Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004, 53:987-992.
16. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., Lees C.W., Balschun T., Lee J., Roberts R., Anderson C.A., Bis J.C., Bumpstead S., Ellinghaus D., Festen E.M., Georges M., Green T., Haritunians T., Jostins L., Latiano A., Mathew C.G., Montgomery G.W., Prescott N.J., Raychaudhuri S., Rotter J.I., Schumm P., Sharma Y., Simms L.A., Taylor K.D., Whiteman D., Wijmenga C., Baldassano R.N., Barclay M., Bayless T.M., Brand S., Buning C., Cohen A., Colombel J.F., Cottone M., Stronati L., Denson T., de V.M., D'Inca R., Dubinsky M., Edwards C., Florin T., Franchimont D., Gearry R., Glas J., Van G.A., Guthery S.L., Halfvarson J., Verspaget H.W., Hugot J.P., Karban A., Laukens D., Lawrance I., Lemann M., Levine A., Libioulle C., Louis E., Mowat C., Newman W., Panes J., Phillips A., Proctor D.D., Regueiro M., Russell R., Rutgeerts P., Sanderson J., Sans M., Seibold F., Steinhart A.H., Stokkers P.C., Torkvist L., Kullak-Ublick G., Wilson D., Walters T., Targan S.R., Brant S.R., Rioux J.D., D'Amato M., Weersma R.K., Kugathasan S., Griffiths A.M., Mansfield J.C., Vermeire S., Duerr R.H., Silverberg M.S., Satsangi J., Schreiber S., Cho J.H., Annese V., Hakonarson H., Daly M.J., Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genetics 2010, 42:1118-1125.
17. Goossens P., Gijbels M.J., Zernecke A., Eijgelaar W., Vergouwe M.N., van d.M., Vanderlocht I., Beckers J., Buurman L., Daemen W.A., Kalinke M.J., Weber U., Lutgens C., de Winther E.M.P. Myeloid type I interferon signaling promotes atherosclerosis by stimulating macrophage recruitment to lesions. Cell Metabolism 2010, 12:142-153.
18. Gordon S.M., Chaix J., Rupp L.J., Wu J., Madera S., Sun J.C., Lindsten T., Reiner S.L. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012, 36:55-67.
19. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
20. Hugot J.P., Laurent-Puig P., Gower-Rousseau C., Olson J.M., Lee J.C., Beaugerie L., Naom I., Dupas J.L., Van G.A., Orholm M., Bonaiti-Pellie C., Weissenbach J., Mathew C.G., Lennard-Jones J.E., Cortot A., Colombel J.F., Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996, 379:821-823.
21. Jiang K., Zhong B., Ritchey C., Gilvary D.L., Hong-Geller E., Wei S., Djeu J.Y. Regulation of Akt-dependent cell survival by Syk and Rac. Blood 2003, 101:236-244.
22. Le Bouteiller P., Barakonyi A., Giustiniani J., Lenfant F., Marie-Cardine A., guerre-Girr M., Rabot M., Hilgert I., Mami-Chouaib F., Tabiasco J., Boumsell L., Bensussan A. Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:16963-16968.
23. Lebeis S.L., Bommarius B., Parkos C.A., Sherman M.A., Kalman D. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. Journal of Immunology 2007, 179:566-577.
24. Leitner J., Drobits K., Pickl W.F., Majdic O., Zlabinger G., Steinberger P. The effects of Cyclosporine A and azathioprine on human T cells activated by different costimulatory signals. Immunology Letters 2011, 140:74-80.
25. Lennard L. The clinical pharmacology of 6-mercaptopurine. European Journal of Clinical Pharmacology 1992, 43:329-339.
26. Lesage S., Zouali H., Cezard J.P., Colombel J.F., Belaiche J., Almer S., Tysk C., O'Morain C., Gassull M., Binder V., Finkel Y., Modigliani R., Gower-Rousseau C., Macry J., Merlin F., Chamaillard M., Jannot A.S., Thomas G., Hugot J.P. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. American Journal of Human Genetics 2002, 70:845-857.
27. Maiza H., Leca G., Mansur I.G., Schiavon V., Boumsell L., Bensussan A. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. Journal of Experimental Medicine 1993, 178:1121-1126.
28. Marks D.J., Rahman F.Z., Sewell G.W., Segal A.W. Crohn's disease: an immune deficiency state. Clinical Reviews in Allergy and Immunology 2010, 38:20-31.
29. Massey D.C., Parkes M. Genome-wide association scanning highlights two autophagy genes. ATG16L1 and IRGM, as being significantly associated with Crohn's disease. Autophagy 2007, 3:649-651.
30. Morice W.G. The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders. American Journal of Clinical Pathology 2007, 127:881-886.
31. Murdaca G., Colombo B.M., Cagnati P., Gulli R., Spano F., Puppo F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224:309-317.
32. Murray J.E., Merrill J.P., Harrison J.H., Wilson R.E., Dammin G.J. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. New England Journal of Medicine 1963, 268:1315-1323.
33. Obata-Onai A., Hashimoto S., Onai N., Kurachi M., Nagai S., Shizuno K., Nagahata T., Matsushima K. Comprehensive gene expression analysis of human NK cells and CD8(+) T lymphocytes. International Immunology 2002, 14:1085-1098.
34. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
35. Ohno S., Sato T., Kohu K., Takeda K., Okumura K., Satake M., Habu S. Runx proteins are involved in regulation of CD122, Ly49 family and IFN-gamma expression during NK cell differentiation. International Immunology 2008, 20:71-79.
36. Quemeneur L., Gerland L.M., Flacher M., Ffrench M., Revillard J.P., Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. Journal of Immunology 2003, 170:4986-4995.
37. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
38. Rioux J.D., Daly M.J., Silverberg M.S., Lindblad K., Steinhart H., Cohen Z., Delmonte T., Kocher K., Miller K., Guschwan S., Kulbokas E.J., O'Leary S., Winchester E., Dewar K., Green T., Stone V., Chow C., Cohen A., Langelier D., Lapointe G., Gaudet D., Faith J., Branco N., Bull S.B., McLeod R.S., Griffiths A.M., Bitton A., Greenberg G.R., Lander E.S., Siminovitch K.A., Hudson T.J. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nature Genetics 2001, 29:223-228.
39. Samarajiwa S.A., Forster S., Auchettl K., Hertzog P.J. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Research 2009, 37:D852-D857.
40. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
41. Smith A.M., Rahman F.Z., Hayee B., Graham S.J., Marks D.J., Sewell G.W., Palmer C.D., Wilde J., Foxwell B.M., Gloger I.S., Sweeting T., Marsh M., Walker A.P., Bloom S.L., Segal A.W. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease. Journal of Experimental Medicine 2009, 206:1883-1897.
42. Steel A.W., Mela C.M., Lindsay J.O., Gazzard B.G., Goodier M.R. Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Alimentary Pharmacology and Therapeutics 2011, 33:115-126.
43. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:15545-15550.
44. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., Diemer K., Muruganujan A., Narechania A. PANTHER: a library of protein families and subfamilies indexed by function. Genome Research 2003, 13:2129-2141.
45. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., Lehr H.A., Wirtz S., Becker C., Atreya R., Mudter J., Hildner K., Bartsch B., Holtmann M., Blumberg R., Walczak H., Iven H., Galle P.R., Ahmadian M.R., Neurath M.F. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. Journal of Clinical Investigation 2003, 111:1133-1145.
46. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:5116-5121.
47. van Baarsen L.G., van der Pouw Kraan T.C., Kragt J.J., Baggen J.M., Rustenburg F., Hooper T., Meilof J.F., Fero M.J., Dijkstra C.D., Polman C.H., Verweij C.L. A subtype of multiple sclerosis defined by an activated immune defense program. Genes and Immunity 2006, 7:522-531.
48. van Bodegraven A.A. Haemostasis in inflammatory bowel diseases: clinical relevance. Scandinavian Journal of Gastroenterology. Supplement 2003, 239:51-62.
49. van der Pouw Kraan C.T., Baggen J.M., van Bodegraven A.A., Mulder C.J., Zwiers A., Geerts D., Kraal G., Horrevoets A.J., Bouma G. Defective IL-1A expression in patients with Crohn's disease is related to attenuated MAP3K4 signaling. Human Immunology 2012, 73:912-919.
50. van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G., Voskuyl A.E., Rustenburg F., Baggen J.M., Ibrahim S.M., Fero M., Dijkmans B.A., Tak P.P., Verweij C.L. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Annals of the Rheumatic Diseases 2007, 66:1008-1014.
51. van Schaik F.D., van Oijen M.G., Smeets H.M., van der Heijden G.J., Siersema P.D., Oldenburg B. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012, 61:235-240.
52. Weersma R.K., Zhou L., Nolte I.M., van der S.G., van Dullemen H.M., Oosterom E., Bok L., Peppelenbosch M.P., Faber K.N., Kleibeuker J.H., Dijkstra G. Runt-related transcription factor 3 is associated with ulcerative colitis and shows epistasis with solute carrier family 22, members 4 and 5. Inflammatory Bowel Disease 2008, 14:1615-1622.
53. Xu Y., Xu Q., Ni S., Liu F., Cai G., Wu F., Ye X., Meng X., Mougin B., Cai S., Du X. Decrease in natural killer cell associated gene expression as a major characteristic of the immune status in the bloodstream of colorectal cancer patients. Cancer Biology and Therapy 2011, 11:188-195.
54. Zambon A.C., Zhang L., Minovitsky S., Kanter J.R., Prabhakar S., Salomonis N., Vranizan K., Dubchak I., Conklin B.R., Insel P.A. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:8561-8566.